Characterization of Heart Failure With Preserved Ejection Fraction

Status Recruiting

Clinical Trial Summary

The goals of this research will be to define some of the mechanisms underlying the progression and complications of heart failure (HF) with preserved left ventricular ejection fraction (HFPEF) Aim 1: to evaluate the differences in cardiac structure, function and fibrosis markers through the spectrum of HF stages in order to deepen the understanding of the pathophysiology driving HF progression. Aim 2: to define the mechanisms by which HF risk factors, such as hypertension, diabetes, obesity, and renal insufficiency, interact with age to increase HF risk, and to evaluate the role of precipitating factors such as myocardial ischemia, atrial fibrillation in HFPEF. Aim 3: to determine prognostic factors in HFPEF patients, by following these patients over time. Accordingly the investigators will correlate baseline data (echocardiographic, MRI or biomarkers) with incident cardiovascular events and determine whether these measures provide incremental prognostic information beyond clinical characteristics.

Clinical Trial Description

Heart failure (HF) is a prevalent and complex clinical syndrome characterized by significant morbidity and mortality. HF patients are classified into two major groups based on their left ventricular ejection fraction (LVEF): heart failure with reduced ejection fraction (HFrEF) (LVEF < 40%) and heart failure with preserved ejection fraction (HFpEF) (LVEF ≥ 50%). These groups exhibit distinct clinical and biological characteristics, and their underlying pathophysiology have been thoroughly investigated. However, HFpEF, which represents more than 50% of HF cases, remains a poorly understood disease with limited therapeutic options Several proposed mechanisms contribute to the development of HFpEF, including systemic inflammation, microvascular dysfunction, cardiometabolic abnormalities, and interstitial fibrosis. The aim of our research programm is to understand the differences between the pathophysiology of this syndrome compared to that of heart failure with reduced EF, with a focus on cardiac fibrosis and metabolism. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03197350
Study type	Interventional
Source	Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Contact	Anne-Catherine Pouleur
Phone	003227646600
Email	anne-catherine.pouleur@uclouvain.be
Status	Recruiting
Phase	N/A
Start date	December 4, 2014
Completion date	December 2028

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03785171` - Predicative Value of Multimodal MRI in Moyamoya Disease
Not yet recruiting	`NCT03726788` - Intra Articular Injection of Botulinum Toxin Versus Corticoids in Gonarthrosis	Phase 2
Active, not recruiting	`NCT01956409` - Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis	Phase 4
Completed	`NCT01660841` - Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging	Phase 3
Recruiting	`NCT03635619` - The Application of 3T MRI in Esophageal Cancer
Recruiting	`NCT03658343` - T2* MRI Analysis for Sarcoma	N/A
Recruiting	`NCT04555642` - Early Diagnosis of Therapy-associated Cardiotoxicity Basing on Multi-tracer Multimodality PET/MRI
Active, not recruiting	`NCT03441867` - Neuroimaging Biomarker for Seizures	N/A
Recruiting	`NCT04850001` - Cognitive Decline in Asymptomatic Intracranial Stenosis Patients: A 1-Year Follow-Up Study
Not yet recruiting	`NCT05816213` - Point-of-care Low-field MRI in Acute Stroke
Active, not recruiting	`NCT05498623` - MR Fingerprinting for Diagnostic of Prostate Cancer
Recruiting	`NCT04257747` - Qualitative and Quantitative Evaluation of Vascular Flows of Radial, Ulnar and Interdigital Arterial Trees Under Normal and Pathological Conditions by 3 Tesla MRI	N/A
Recruiting	`NCT04996615` - Artificial Intelligence Analysis for Magnetic Resonance Imaging in Screening Breast Cancer in High-risk Women
Recruiting	`NCT05889117` - Brain Stimulation for Concussion	N/A
Completed	`NCT02540967` - Drug Use Investigation of Gadovist.
Completed	`NCT05103189` - 4D-flow Cardiac MRI to Assess Pulmonary Arterial Pressure in Pulmonary Hypertension	N/A
Completed	`NCT02567318` - Is the Volume of the Caudate Nuclei Associated With Area of Secondary Hyperalgesia?	N/A
Recruiting	`NCT02834585` - Magnetic Resonance Imaging or Ultrasound in Soft Tissue Tumors (MUSTT)	N/A
Active, not recruiting	`NCT02446665` - Disease Status in Primary Sclerosing Cholangitis by Elastography	N/A
Completed	`NCT01721785` - Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.